Recombinant Equine IL-1ra/IL-1F3 Protein

Catalog #: 2466-RA
1 Citation Datasheet / COA / SDS

Carrier Free

Catalog #	Availability	Size / Price	Qty
2466-RA-050/CF

With Carrier

Catalog #	Availability	Size / Price	Qty
2466-RA-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Citations (1)

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Equine IL-1ra/IL-1F3 Protein Summary

Product Specifications

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit IL-1 alpha -dependent proliferation in D10.G4.1 mouse helper T cells. Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272. The ED₅₀ for this effect is 0.75-3.0 µg/mL in the presence of 50 pg/mL of rhIL-1 alpha.

Source

E. coli-derived equine IL-1ra/IL-1F3 protein
His26-Gln177, with an N-terminal Met

Accession #

O18999.1

N-terminal Sequence
Analysis

Met

Predicted Molecular Mass

17.5 kDa

Product Datasheets

2466-RA (with carrier)

Product Datasheet

COA

SDS

2466-RA/CF (carrier free)

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

2466-RA

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS and DTT with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

2466-RA/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS and DTT.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: IL-1ra/IL-1F3

Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22 - 25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity (1 - 3). It is a member of the IL-1 family of proteins that includes IL-1 alpha and IL-1 beta. Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a beta -trefoil structure, and all are believed to have evolved from a common ancestral gene (1 - 4). Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site (3, 5, 6). Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes.

There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( alpha or beta ) binding to the same receptor. This results in receptor ligation without activation (1, 7). The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI (1, 2, 8, 9).

References

Arend, W.P. et al. (1998) Annu. Rev. Immunol. 16:27.
Roux-Lombard, P. (1998) Eur. Cytokine Netw. 9:565.
Dayer-J-M. (2002) Clin. Exp. Rheumatol. 20(27):S14.
Eisenberg, S.P. et al. (1991) Proc. Natl. Acad. Sci. USA 88:5232.
Kato, H. et al. (1997) Vet. Immunol. Immunopathol. 56:221.
Howard, R.D. et al. (1998) Am. J. Vet. Res. 59:712.
Dinarello, C.A. (1997) Semin. Oncol. (Suppl 9):S9.
Irikura, V.M. et al. (2002) J. Immunol. 169:393.
Arend, W.P. and C. Gabay (2000) Arth. Res. 2:245.

Long Name

Interleukin 1 Receptor Antagonist

Entrez Gene IDs

3557 (Human); 16181 (Mouse); 60582 (Rat); 397499 (Porcine)

Alternate Names

DIRA; ICIL-1ra; IL1F3; IL-1F3; IL1ra; IL-1ra; IL-1ra3; IL1RN; IL-1RN; interleukin 1 receptor antagonist; IRAP; MVCD4

Related Research Areas

Citation for Recombinant Equine IL-1ra/IL-1F3 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1